Logo

BMS Receive the CHMP's Positive Opinion Recommending Approval of Opdivo (nivolumab) + Yervoy (ipilimumab) for dMMR or MSI-H mCRC After Prior Chemotherapy

Share this

BMS Receive the CHMP's Positive Opinion Recommending Approval of Opdivo (nivolumab) + Yervoy (ipilimumab) for dMMR or MSI-H mCRC After Prior Chemotherapy

Shots:

  • The opinion is based on P-II CheckMate -142 study assessing Opdivo + Yervoy in patients with mismatch repair deficient or microsatellite instability–high metastatic colorectal cancer whose disease had progressed during or after prior treatment with CT
  • If approved- Opdivo in combination with Yervoy will be the first dual immunotherapy approved in the EU in gastrointestinal cancer
  • The combination regimen receives the US FDA’s approval in Jul’2018 for adults and pediatric patients aged ≥12yrs. with MSI-H or dMMR mCRC that has progressed following treatment with CT. The dual regimen receives PMDA approval in Sept’2020 for MSI-H unresectable- advanced or recurrent colorectal cancer progressing after CT

  Ref: BMS | Image: BMS 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions